MSFT 416.9992 0.2113% AAPL 231.83 0.0216% NVDA 138.895 2.3394% GOOGL 163.53 -0.9869% GOOG 165.1 -0.9836% AMZN 187.78 0.4762% META 578.1245 0.2314% AVGO 183.5976 3.8331% TSLA 220.4371 -0.4034% TSM 207.9713 10.9299% LLY 917.515 -0.5652% V 289.845 0.8086% JPM 224.705 0.4762% UNH 568.2 -0.5496% NVO 118.43 0.3389% WMT 80.845 -0.4617% LVMUY 131.3 0.6439% XOM 120.36 -0.2486% LVMHF 659.0 1.0345% MA 513.11 -0.1867%
Abbott Laboratories
ABT Details
Abbott Laboratories (NYSE: ABT) is a healthcare corporation that develops, manufactures, and sells various products. Its products are primarily sold to retailers, wholesalers, hospitals, healthcare institutes, laboratories, doctors' offices, and government agencies worldwide. The company's four operating segments are 1) Established Pharmaceutical Products, 2) Nutritional Products, 3) Diagnostic Products, and 4) Medical Devices.
Latest News:
9MFY21 Results:
Key Risks:
Outlook:
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
ABT Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
ABT's share price has surged 22.37% in the past six months and is currently trading towards the higher end of its 52-weeks range of USD 105.36 to USD 139.27. The stock is currently trading above its 50 and 200 DMA levels, and its RSI Index is at 62.37. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 130.31.
Considering the uptick in the stock price and current valuation, we believe the decent business fundamentals are adequately reflected at current trading levels. Hence, we recommend a "Sell" rating on the stock at the current price of USD 135.78, up 0.60%, as of December 21, 2021, at 9:34 AM ET.
*All forecasted figures and Industry Information have been taken from REFINITIV.
*The reference data in this report has been partly sourced from REFINITIV.
Fulgent Genetics, Inc.
FLGT Details
Fulgent Genetics, Inc. (NASDAQ: FLGT) is a genetic testing company that specializes in oncology, infectious and rare disorders, and reproductive health. FLGT has integrated next-generation sequencing (NGS) into its technological platform, allowing single-gene testing to include whole gene sequencing and deletion/duplication analysis.
Latest News:
Q3FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
FLGT Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
FLGT's stock price has surged 26.00% in the past week and is currently trading close to the mid-band of its 52-week range of USD 42.51 to USD 189.89. The stock is currently trading far above its 50 and 200 DMA levels, and its RSI Index is at 70.05, indicating an overbought zone. We have valued the stock using the EV/Sales multiple-based relative valuation methodology and arrived at a target price of USD 95.16.
Considering the significant uptick in the stock price in a short span and current valuation, we believe the decent business fundamentals are adequately reflected at current trading levels. Hence, we recommend a "Sell" rating on the stock at the current price of USD 107.24, up 2.13% as of December 21, 2021, at 9:30 AM ET.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Kalkine Equities LLC provides general information about companies and their securities. The information contained in the reports, including any recommendations regarding the value of or transactions in any securities, does not take into account any of your investment objectives, financial situation or needs. Kalkine Equities LLC is not registered as an investment adviser in the U.S. with either the federal or state government. Before you make a decision about whether to invest in any securities, you should take into account your own objectives, financial situation and needs and seek independent financial advice. All information in our reports represents our views as at the date of publication and may change without notice.
Kalkine Media LLC, an affiliate of Kalkine Equities LLC, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.